Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
The Mississippi State Department of Health encourages everyone to get appropriate updated vaccinations to avoid severe ...
Olympic gold medalist gymnast Shawn Johnson East had respiratory syncytial virus-related experiences with all 3 of her ...
Researchers found that vaccination rates decreased as the social vulnerability index quartile increased, especially among ...
This is a sober reminder that the flu can be deadly. Unfortunately, we see many deaths, hospitalizations and other serious ...
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
A Midlands resident has died in what DPH says is the first flu death of the season in South Carolina. COLUMBIA, S.C. — The ...
The South Carolina Department of Public Health (DHP) has confirmed the state's first flu-related death of the season, which ...
Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
Zacks.com on MSN1d
PFE Gets FDA Nod for Expanded Use of RSV Vaccine AbrysvoPfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback